Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
JP Morgan analyst Anupam Rama maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Overweight and lowers the price target f...
UBS analyst David Dai maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and raises the price target from $35 to $38.
Barclays analyst Peter Lawson maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Overweight and raises the price target f...
Syndax Pharmaceuticals (NASDAQ:SNDX) reported quarterly losses of $(0.70) per share which beat the analyst consensus estimate o...
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and maintains...
